DSIP Regulatory Status: The 2026 FDA Vote

If the name is unfamiliar, that is because the retail market does not use it. Emideltide is the established name for the synthetic nonapeptide sold and discussed everywhere else as DSIP or delta sleep-inducing peptide. Same substance, different register — the regulatory documents use one name and the supplement listings use the other.

That matters practically. Someone searching for FDA news about "DSIP" may find nothing and conclude nothing has happened. Something has.

The road here runs through a different list.

Under section 503A of the Federal Food, Drug, and Cosmetic Act, the FDA maintains an interim list of nominated bulk drug substances sorted into categories. Category 2 is the one for substances the agency has identified as raising significant safety risks; a pharmacy may not compound with a substance placed there.

In April 2026, the FDA removed twelve peptide substances from Category 2. DSIP was among them, alongside Epitalon and MOTS-c.

Two things about those removals are routinely misreported and both need saying.

They were not a safety finding. The removals followed the parties who had nominated the substances withdrawing their nominations. The agency was not announcing that it had reviewed the evidence and found these compounds safe.

Removal from Category 2 does not authorize compounding. Coming off the "do not compound" list is not the same as going onto the "may compound" list. A substance can be on neither, which is a legal nowhere rather than a green light. Sellers who announced in spring 2026 that peptides had been "cleared" were describing something that did not happen.

The July committee meeting was the next step: the question of whether these substances should actually be added to the 503A Bulks List. Six got a recommendation to proceed. DSIP did not.

Even for the six, nothing is finished.

The Pharmacy Compounding Advisory Committee advises. It does not decide. Formally adding a substance to the 503A Bulks List requires notice-and-comment rulemaking by the FDA — a proposed rule, a public comment period, a final rule. As of September 2026 that process has not been completed for any of these peptides.

So the accurate summary of the whole category, DSIP included, is this: none of these substances is FDA-approved for any indication, none has been formally added to the 503A Bulks List, and one of them was specifically not recommended for it.

We are not going to guess what happens next. The FDA may or may not follow the committee on the six. DSIP may or may not be revisited. Predicting a regulator is not a service to anyone, and a prediction on a page like this reads as reassurance whether or not it is meant that way.

Plainly: DSIP is the weakest position in this category, on two counts at once.

The evidence is thin. The human sleep literature is a small number of old, inconsistent studies with no modern replication, which is the subject of the sleep evidence page.

And the regulatory standing is the one that a committee looked at directly and declined to advance. Products still being sold as DSIP are generally labeled for research use, and a "research use only" label is not a quality standard, a purity guarantee, or a medicine.

What we can offer is the thing that is useful regardless of how the rulemaking lands: find out why you are not sleeping. That means a baseline panel, screening for sleep apnea where the history suggests it, and a real conversation about alcohol, caffeine, mood and schedule. That work has better evidence behind it than any peptide on this page, and it does not depend on a federal register notice.